Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances

Hamilton, Bermuda, Aug. 16, 2024 (GLOBE NEWSWIRE) --

Altamira Medica Ltd. (“Altamira” or the “Company”), an associate company of Altamira Therapeutics Ltd. (Nasdaq:CYTO), today announced that its preservative-free, drug-free Bentrio® nasal spray for allergic rhinitis was tested successfully for the absence of more than 230 prohibited substances listed by the World Anti-Doping Agency (WADA). This finding further confirms Bentrio’s suitability for athletes who must comply with antidoping regulations but at the same time need to protect themselves against airborne allergens or other particles.